{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:08:43Z","timestamp":1778522923201,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K06796"],"award-info":[{"award-number":["18K06796"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.dmpk.2024.100998","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T02:06:05Z","timestamp":1705284365000},"page":"100998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder"],"prefix":"10.1016","volume":"56","author":[{"given":"Mizuki","family":"Shiho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaku","family":"Akashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimako","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-2184","authenticated-orcid":false,"given":"Takashi","family":"Okura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2024.100998_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100998_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100998_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00192-014-2557-9","article-title":"Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?","volume":"26","author":"Sacco","year":"2015","journal-title":"Int Urogynecol J"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100998_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s002400050038","article-title":"Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation","volume":"26","author":"Goepel","year":"1998","journal-title":"Urol Res"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100998_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.urology.2011.05.011","article-title":"Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard","volume":"78","author":"Yoshida","year":"2011","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100998_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5213\/inj.2012.16.3.107","article-title":"Characterization of bladder selectivity of antimuscarinic agents on the basis of in\u00a0vivo drug-receptor binding","volume":"16","author":"Yamada","year":"2012","journal-title":"Int Neurourol J"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100998_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1248\/yakushi1947.117.2_65","article-title":"Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory","volume":"117","author":"Sawada","year":"1997","journal-title":"Yakugaku Zasshi"},{"issue":"4","key":"10.1016\/j.dmpk.2024.100998_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients","volume":"33","author":"Nordstr\u00f6m","year":"1993","journal-title":"Biol Psychiatr"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100998_bib9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.1476-5381.1995.tb16386.x","article-title":"Histamine H 1 receptor occupancy in human brains after single oral doses of histamine H 1 antagonists measured by positron emission tomography","volume":"116","author":"Yanai","year":"1995","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2024.100998_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1248\/bpb.30.1297","article-title":"Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects","volume":"30","author":"Takayanagi","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100998_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","article-title":"Target site occupancy: emerging generalizations from clinical and preclinical studies","volume":"122","author":"Grimwood","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100998_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.116.236497","article-title":"Urinary excretion contributes to long-lasting blockade of bladder muscarinic receptors by imidafenacin: effect of bilateral ureteral ligation","volume":"360","author":"Ito","year":"2017","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100998_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.120.000301","article-title":"Possible involvement of muscarinic receptor blockade in mirabegron therapy for patients with overactive bladder","volume":"377","author":"Yamada","year":"2021","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"12","key":"10.1016\/j.dmpk.2024.100998_bib14","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/iju.14696","article-title":"Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder","volume":"28","author":"Yamada","year":"2021","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100998_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1254\/jphs.13193FP","article-title":"Muscarinic receptor binding of the novel radioligand, [3H]imidafenacin in the human bladder and parotid gland","volume":"124","author":"Yoshida","year":"2014","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100998_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1757-5672.2011.00089.x","article-title":"Muscarinic receptor binding of imidafenacin in the human bladder mucosa and detrusor and parotid gland","volume":"3","author":"Seki","year":"2011","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100998_bib17","first-page":"365","article-title":"Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder","volume":"175","author":"Maruyama","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.dmpk.2024.100998_bib18","doi-asserted-by":"crossref","first-page":"920.e1","DOI":"10.1016\/j.urology.2013.01.012","article-title":"Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle","volume":"81","author":"Yoshida","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.dmpk.2024.100998_bib19","series-title":"Solifenacin (vesicare\u00ae) interview form","year":"2020"},{"key":"10.1016\/j.dmpk.2024.100998_bib20","series-title":"Imidafenacin (uritos\u00ae) interview form","year":"2020"},{"key":"10.1016\/j.dmpk.2024.100998_bib21","series-title":"Propiverine (BUP-4\u00ae) interview form","year":"2021"},{"key":"10.1016\/j.dmpk.2024.100998_bib22","series-title":"Tolterodine (detrusitol\u00ae) interview form","year":"2021"},{"key":"10.1016\/j.dmpk.2024.100998_bib23","series-title":"Fesoterodine (toviaz\u00ae) interview form","year":"2022"},{"issue":"9","key":"10.1016\/j.dmpk.2024.100998_bib24","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/dmd.107.016030","article-title":"Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects","volume":"35","author":"Ohmori","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2024.100998_bib25","first-page":"859","article-title":"Bioequivalence study for propiverine hydrochloride fine granule and tablet","volume":"34","author":"Nishimura","year":"2006","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2024.100998_bib26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3999\/jscpt.21.555","article-title":"Phase I study of propiverine hydrochloride\u2014the 1st report: single oral dosing study","volume":"21","author":"Kugimiya","year":"1990","journal-title":"Jpn J Clin Pharmacol Therapeut"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100998_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urology.2013.05.017","article-title":"Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume","volume":"82","author":"Yokoyama","year":"2013","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100998_bib28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/nau.23413","article-title":"Comparative efficacy and tolerability of solifenacin 5 mg\/day versus other oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis","volume":"37","author":"Nazir","year":"2018","journal-title":"Neurourol Urodyn"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:15:17Z","timestamp":1778519717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"alternative-id":["S1347436724000041"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.100998","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.100998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100998"}}